Despite its clinical importance, very little is known about the natural history and molecular underpinnings of lung cancer dissemination and metastasis. Here, we used a genetically engineered mouse model of metastatic lung adenocarcinoma in which cancer cells are fl uorescently marked to determine whether dissemination is an inherent ability or a major acquired phenotype during lung adenocarcinoma metastasis. We fi nd very little evidence for dissemination from oncogenic KRAS-driven hyperplasias or most adenocarcinomas. p53 loss is insuffi cient to drive dissemination but rather enables rare cancer cells in a small fraction of primary adenocarcinomas to gain alterations that drive dissemination. Molecular characterization of disseminated tumor cells indicates that downregulation of the transcription factor Nkx2-1 precedes dissemination. Finally, we show that metastatic primary tumors possess a highly proliferative subpopulation of cells with characteristics matching those of disseminating cells. We propose that dissemination is a major hurdle during the natural course of lung adenocarcinoma metastasis.
INTRODUCTION
Metastasis is a multistep process, and the acquisition of metastatic ability has traditionally been considered a late step in cancer evolution ( 1 ) . Recent evidence in mouse models of breast and pancreatic cancer suggests that cancer cells within premalignant lesions may already possess the ability to disseminate (1) (2) (3) (4) . These observations support a model in which cancer cells leave primary tumors at an early stage of tumor growth, thereby allowing the primary tumor and disseminated cells to accrue genomic alterations independently (5) (6) (7) . This paradigm of metastatic progression is consistent with fi ndings of disparate DNA copy-number alterations in primary tumors and related disseminated cancer cells and metastases in patients ( 5-7 ).
RESEARCH BRIEF
Lung adenocarcinoma is the most common subtype of lung cancer, with more than 90,000 patients diagnosed each year in the United States alone ( 8 ) . Several factors contribute to the poor outcome of patients with lung cancer but, as in most solid tumors, the ability of cancer cells to leave the primary tumors and establish inoperable metastases is a major impediment to successful therapy ( 9 ) . Whether early premalignant lesions in human lungs have an inherent capacity to give rise to disseminated tumor cells (DTC) is a question of both clinical and biological importance. Despite its signifi cance, systems to address the question of whether lung adenocarcinoma metastatic progression conforms to a traditional late-evolution model or a parallel progression model have not been developed. Although these questions would ideally be studied in humans, early lesions are by defi nition small and exist in undiagnosed patients, making their study diffi cult if not impossible. Hence, accurate and tractable genetic models are required to investigate this process.
Human lung adenocarcinoma frequently harbors oncogenic mutations in KRAS and inactivation of the p53 tumorsuppressor pathway ( 10, 11 ) and has been modeled using conditional alleles in mice. Oncogenic Kras G12D has been expressed in lung epithelial cells using transgenic systems, stochastic intrachromosomal recombination, or Cre-mediated deletion of the transcriptional/translational Stop element in loxP-Stop-loxP Kras G12D knock-in mice ( Kras
LSL-G12D/ +
). This single event initiates the stepwise development of lung lesions that closely resemble early-stage atypical adenomatous hyperplasias (AAH), adenomas, and early adenocarcinomas (12) (13) (14) . Concomitant mutation of the p53 tumor suppressor allows the development of overtly invasive and metastatic cancer (15) (16) (17) . Notably, these genetically engineered mouse models of human lung cancer recapitulate the genetic events, histologic appearance of lesions at both the early and late stages, and metastatic ability of the human disease (12) (13) (14) (15) (16) (17) .
Here, we use a series of in vivo mouse models to uncover the kinetics of lung tumor cell dissemination, investigate the importance of p53 loss in this process, and characterize the gene expression changes associated with this critical step of the metastatic cascade.
RESULTS
To analyze cancer cell dissemination at defi ned time points after tumor initiation, we used a system to induce fl uorescently labeled lung tumors. To stably mark all cancer cells, we incorporated a Rosa26 knock-in Cre-reporter allele ( R26 Fig. S1 ). In KPT mice, lung tumors initiated by inhaled viral-Cre express oncogenic Kras G12D , delete p53, and express the red fl uorescent protein tdTomato ( Fig. 1A and B and Supplementary Figs. S1 and S2). We have documented excellent specifi city and sensitivity to detect Tomato positive micro-and macrometastases using fl uorescence microscopy and IHC and quantifying single Tomato positive disseminated cancer cells using fl ow cytometry, confi rming stable marker expression in even the most advanced cancer cells ( Figs. 1B and 2A ; data not shown).
Tumors in KPT mice are initiated synchronously, thus allowing the analysis of cancer cell dissemination at defi ned time points after tumor initiation ( 15, 16 ) . To most accurately compare the ability of early-stage and late-stage lung cancer cells to disseminate, we generated two separate groups of mice, which we called KPT -Late and KPT -Early mice. Tumor initiation with either 5 × 10 6 Adenoviral-Cre or 2 × 10 3 Lentiviral-Cre induced 10 to 50 tumors that included small and large adenomas as well as adenocarcinomas with varying degrees of invasion ( Fig. 1A-C and Supplementary  Fig. S1 ; data not shown). These KPT -Late mice survived 4 to 8 months. To generate KPT -Early mice, we infected KPT mice with 3 × 10 9 Adeno-Cre (600-fold more than for KPT-Late mice), which induced high numbers of early-stage hyperplastic lesions such that the total number of neoplastic cells within the lungs was approximately equal to that in KPT -Late mice. KPT -Early mice became tachypneic approximately 1 month after tumor initiation, and histologic analysis indicated that AAHs had replaced almost the entire lung parenchyma ( Fig. 1A-D and Supplementary Fig. S1 ). The Tomato positive cells that expanded in the lungs of KPT -Early mice displayed histologic and cytologic features of atypical epithelial hyperplasias and expressed lung epithelial markers ( Fig. 1D ) .
The relative tumor burden in KPT -Early and KPT -Late mice was assessed by measuring total lung weight, semiquantitative genotyping of total lung DNA for recombination of the Kras LSL-G12D and p53 fl oxed alleles, and direct quantifi cation of Tomato positive tumor cells by IHC ( Fig. 1E and F and Supplementary Fig. S2 ). Collectively, these analyses indicate that similar numbers of neoplastic cells are present in KPTEarly mice with massive numbers of hyperplastic lesions and in KPT -Late mice with distinct solid tumor masses within larger areas of normal lung. We have additionally confi rmed a recombination effi ciency of >95% for the Kras and p53 fl oxed alleles in purifi ed Tomato positive cells from both KPT -Early and KPT -Late mice ( Supplementary Fig. S2 ). By matching both the neoplastic cell number and core genetic alterations in both subsets of mice, this system enables the comparison of DTCs between the two groups.
Dissemination of cancer cells into the blood and lymphatic systems as well as directly into the pleural cavity represents an early stage of metastatic spread. The presence of lung cancer cells in the pleural cavity of human patients with lung adenocarcinoma has been assessed by intraoperative pleural lavage cytology ( 19, 20 ) . Cancer cells in the pleural cavity correlate with lymphatic invasion and are a strong predictor of distant metastatic relapse, even in patients with stage I disease ( 19, 20 ) . Malignant pleural effusions as well as the high prevalence of pleural metastases at diagnosis and relapse further suggest that metastatic lung cancer cells frequently invade into the pleural cavity.
The high levels of epithelial hyperplasia in KPT -Early mice represent a large reservoir of "premalignant" tumor cells that, if capable of disseminating, should be detectable in the pleural cavity and vascular circulation of these mice. To determine whether lung epithelial tumor cells are inherently endowed with the ability to disseminate, we performed Fig. 2A and B ) . To exclude the possibility that we failed to detect DTCs in the KPT-Early mice for technical reasons related to the fl ow cytometry preparation, we directly transplanted unfractionated pleural cavity cells from these mice into syngeneic recipient animals. None of the recipient mice injected with pleural cavity cells from KPT-Early mice developed tumors ( Fig. 2F ). 
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We and others have previously shown that not all Kras
fl ox/fl ox late-time point tumor-bearing mice have macrometastases ( 15, 16 ) . However, we were surprised to fi nd that not all KPT -Late mice had DTCs, and that the number of DTCs was very diverse across mice within this group ( Fig. 2B and Supplementary Fig. S3 ). The presence and number of DTCs was not related to the total tumor burden or time after tumor initiation but did correlate with the number of metastases ( Fig. 2B-D and Supplementary Fig. S4 ). The presence of metastases seeded through hematogenous spread suggests that circulating tumor cells (CTC) in the blood should also be detectable using fl ow cytometry. We identifi ed CTCs in two KPT -Late animals that also exhibited high numbers of pleural cavity DTCs ( Supplementary Fig. S4 ). Despite extremely high total tumor burden, large numbers of tumors, and relatively long times after tumor initiation, approximately half of the KPT -Late mice had no DTCs in their pleural cavity ( Fig. 2B-D ) .
To determine whether DTCs from KPT -Late mice have tumor-seeding potential, we transplanted a fraction of the pleural cells into syngeneic recipient mice. Tomato Inactivation of the p53 tumor suppressor is a common event in human lung adenocarcinoma and is associated with more advanced disease, metastatic spread, and poor patient outcome. p53 could function to inhibit dissemination or could strictly limit metastatic seeding and/or growth in distant organs. To clarify how p53 inactivation contributes to cancer progression and metastasis and therefore patient outcome, we generated Kras
LSL-tdTomato/+ ( KT ) mice, in which the tumor cells express tdTomato but remain p53-profi cient. As with KPT mice, we generated cohorts of KT mice infected with high-titer Adeno-Cre (3 × 10 9
; KT-Early mice) or low-titer Adeno-Cre (10 7 ; KT -Late; Supplementary Fig. S5 ). Consistent with published studies, KT -Late mice developed large primary tumors (with total tumor burden approaching that of KPTLate mice), but did not develop macrometastases ( 12 , 16 ) . Flow cytometry and direct fl uorescent microscopy indicated that KT -Late mice had neither micrometastases nor cancer cells in the blood ( Supplementary Fig. S4 and data not shown). In addition, pleural DTCs were not detected in KT -Early mice ( Fig. 2G ) . This suggests that even in the absence of engineered tumor-suppressor loss, very rare tumors can independently evolve mechanisms that allow dissemination within the timeframe of their growth in vivo in this model. Consistent with the general absence of Tomato positive cancer cells from KT mice, transplantation of pleural cavity cells from these mice into syngeneic recipient did not generate metastases ( Fig. 2H ) . These results indicate that at least one major function of p53 is to directly or indirectly regulate phenotypes associated with cancer cell dissemination. In addition, our observation that not all KPT -Late mice have DTCs suggests that, contrary to work in other systems ( 21, 22 ) , p53 loss per se is insuffi cient to drive dissemination but rather enables rare cancer cells in a small fraction of primary tumors to gain the required alterations that drive dissemination.
Fluorescent marking in KPT mice allows for the accurate detection of DTCs but does not uncover how many individual tumors are the source of disseminating cancer cells at late time points. Systemic effects, including the ill health of late-stage animals, minor differences in individual's genetic background, and a single advanced tumor's ability to alter the host in such a way as to induce malignant progression of otherwise benign primary tumors, could induce a large number of tumors to synchronously gain the capacity to disseminate ( 23 ) . In addition, local paracrine effects, including the infl ammatory environment, could induce multiple tumors in close proximity to each other to disseminate. On the basis of these considerations, we used two separate systems to determine whether most or all of the cancer cells in the pleural cavity of each KPT -Late mouse are from a single advanced tumor, or whether large numbers of tumors synchronously gain the capacity to disseminate.
To fl uorescently mark distinct tumors, we generated a Creregulated multicolor Rosa26 knock-in reporter allele based on the recombination of heterotypic lox sites surrounding a stop cassette and three unique fl uorescent proteins ( R26 
R26
Motley/ + ( KPM ) mice generated red, cyan, and yellow fl uorescent tumors ( Fig. 3A and Supplementary Fig. S6 ). Despite the presence of multiple large tumors with typical adenocarcinoma features, including high nuclear-to-cytoplasmic ratio, giant cells, and dedifferentiated solid structure, DTCs in each animal were generally only one or two of the three possible colors ( Fig. 3B ) .
To complement our three-color KPM system, we infected KPT mice with a pool of lentiviral vectors that express Cre and carry a unique nucleotide barcode to generate tumors that each have a stably integrated nucleotide barcode ( Fig. 3C ;  ref. 16 ). To determine whether cancer cells in the pleural cavity were from one or more tumors, we isolated these DTCs and sequenced their barcode region. PCR amplifi cation and Sanger sequencing of the barcode region from eight DTC samples indicated that cancer cells in the pleural cavity are seeded from one dominant parental tumor ( Fig. 3D ) . Cloning and sequencing of the barcode amplicon confi rmed that DTCs are largely derived from a single primary tumor ( Fig. 3E ) . Collectively, our fl uorescent and genetic clonal marking experiments indicate that in lung adenocarcinoma 
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the ability to disseminate is uniquely gained in a cell-intrinsic manner by rare tumors. The diffi culty in identifying and purifying DTCs from patients and the paucity of methods to isolate these cells from autochthonous mouse models have limited their molecular analysis. We and others have previously identifi ed the transcription factor Nkx2-1 as a critical suppressor of lung adenocarcinoma progression and metastatic ability ( 16 , 25 , 26 ) . In our initial study, we were unable to determine whether both Nkx2-1 positive and Nkx2-1 negative cells are equally capable of disseminating but differentially able to seed or grow at distant sites, or whether Nkx2-1 negative cells have a unique ability to leave the primary tumor (Supplementary Fig. S7; ref. 16 ).
To address this question, we purifi ed Tomato positive cancer cells from primary tumors, disseminated cancer cells, as well as metastases from lymph nodes and pleura. We used the lentiviral barcode sequences to determine the relationship between the primary tumors, DTCs, and metastases ( Fig. 4A ) . This allowed us to segregate primary tumors into those that had seeded metastases (T Met ) and those that had not (T nonMet ), and allowed us to choose samples based on the known relationship of the T Met tumors, DTCs, and metastases in individual mice ( Fig. 4A ) . This barcode analysis indicated that these data represent the gene expression state of nine individual metastatic families ( Fig. 4A ) . We determined the expression of Nkx2-1 and its canonical target gene surfactant protein B (Sftpb ) by qRT-PCR on cancer cells from each stage of metastatic progression. In all but one of the families both Nkx2-1 and Sftpb were downregulated 10-fold or more in DTCs compared with primary tumors ( Fig. 4A-C ) .
Our ability to identify the metastatic primary tumors (T Met ) also allowed us to estimate the fraction of the primary tumor composed of the metastatic subclone. Nkx2-1 and Sftpb expression was variable in the T Met tumors with three of four T Met tumors being nearly indistinguishable from T nonMet tumors ( Fig. 4B and C ) . Immunohistochemical staining also indicated that the Nkx2-1 negative areas comprised diverse proportions in T Met tumors (Supplementary Fig. S8 ). Given the variable size in the metastatic subclones, we investigated whether Nkx2-1 negative areas have a selective advantage that drives their expansion within the primary tumor. IHC for BrdUrd incorporation, phosphorylated histone H3 (H3P), and Ki67 all uncovered increased proliferation of Nkx2-1 negative areas ( Fig. 4D-F  and Supplementary Fig. S8 ). Importantly, Nkx2-1 negative areas were consistently more proliferative than the adjacent Nkx2-1 positive areas within the same tumor, and metastases were also more proliferative than Nkx2-1 positive primary lung tumors ( Fig. 4D-F ) . Conversely, cell death was low and unaltered in Nkx2-1 negative primary tumor areas and metastases, suggesting that increased proliferation rather than evasion of cell death contributes to the competitive advantage of cancer cells within Nkx2-1 negative areas (Supplementary Fig. S8 ). 349T5  133T6  608T8  545T5  355T2  343T3  772T6  299T1  349T4  545T4  374T7  349DTC  133DTC  608DTC  355DTC  772DTC  374DTC  349LN  545LN  133LN  608LN  355LN  343LN  772LN  374LN  299Met  349Met  545Met  133Met 349T5  133T6  608T8  545T5  355T2  343T3  772T6  299T1  349T4  545T4  374T7  349DTC  133DTC  608DTC  355DTC  772DTC  374DTC  349LN  545LN  133LN  608LN  355LN  343LN  772LN  374LN  299Met  349Met  545Met  133Met  608Met Metastases T nonMet T Met DTCs  Metastases   299T1  349T4  545T4  374T7   349DTC   133DTC  608DTC  355DTC  772DTC   374DTC   349LN  545LN   133LN  608LN  355LN   343LN   772LN   374LN   299Met  349Met 
DISCUSSION
These studies were initiated to gain insight into whether lung tumors have an inherent ability to disseminate or whether this is a major limiting step of lung adenocarcinoma metastasis. Our results indicate that neither lung epithelial hyperplasias nor most tumors that exist 4 to 8 months after tumor initiation have any ability to shed cancer cells. Our data indicate that the expression of oncogenic Kras and loss of p53 are insuffi cient to enable lung tumor cells to disseminate, but rather create a permissive genomic context that allows rare tumors to transition to an invasive and metastatic state characterized by downregulation of the lung differentiation transcription factor Nkx2-1. Importantly, some KPT -Late mice with approximately 1 g of tumor mass have no DTCs, whereas others have >1,000 pleural DTCs derived from a single tumor. We propose that dissemination is a major hurdle during the natural course of lung adenocarcinoma metastasis.
Unlike in pancreatic and breast cancers in which tumor cells have been suggested to disseminate from premalignant lesions ( 2, 3 ), lung adenocarcinomas begin as benign proliferative lesions with a very limited ability to initiate the metastatic cascade. Our data suggest that even once tumors lose p53 and progress to exhibiting the canonical features of adenocarcinoma, they still require additional alterations to physically escape the primary tumor. Although different combinations of oncogenic and tumor-suppressor alterations could drive metastasis through unique mechanisms, disruption of the p53 pathways can allow cancer cells to acquire alterations that allow loss of differentiation before dissemination.
Our data suggest that the ability to seed metastases early during tumor growth is not a general feature of carcinomas that develop in different organs, but rather that the early dissemination from breast and pancreatic cancer likely represents cell type-specifi c responses to the initiating oncogenic events or the specifi c environmental context within those organs or early lesions. We speculate that distinct cancer types and subtypes will have dramatically different thresholds for each step of the metastatic cascade. Although pancreatic cancer cells may disseminate from early pancreatic intraepithelial neoplasms, these DTCs seem to have limited-to-no metastasis seeding ability ( 3 ). These primary pancreatic tumors thus require the acquisition of additional traits to allow their DTCs to overcome at least one later step of metastasis. Alternately, for cancers in which dissemination requires a considerable change in cell state, including the fraction of human lung adenocarcinomas driven by the molecular mechanisms described in this autochthonous mouse model, disseminated cancer cells should be viewed as clinically meaningful agents of metastatic spread. These initial disseminated cancer cells may already possess many, if not all, of the attributes required to form metastases. As the molecular characterization of CTCs in patients becomes more feasible, these types of studies will help in interpreting the clinical signifi cance of these cancer cells.
Most patients with lung adenocarcinoma with sub-1-cm lung tumors do not present with lymph node metastases or recur with metachronous distant metastatic disease (27) (28) (29) (30) .
Our data suggest that this is likely due to the inability of cells to disseminate, rather than the general ineffi ciency of each step of metastatic cascade. Unfortunately, lung adenocarcinoma often presents as overtly metastatic disease, and even patients who have potentially curative surgery often relapse due to the presence of metastases that were below the detection level at the time of diagnosis. Defi ning the molecular mediators of lung adenocarcinoma metastasis in this and other genomic contexts will be an important area of future investigation.
METHODS

Mouse Strains
Kras LSL-G12D , p53
fl ox
, and Rosa26 LSL-tdTomato mice have been described previously ( 12 , 15 , 18 , 31 ) . We generated mice with the Kras and the R26 LSL-tdTomato in cis on chromosome 6, guaranteeing retention of the R26 LSL-tdTomato allele even in genomically unstable tumors. Wild-type male 6-to 10-week-old B6129SF1/J recipients were from The Jackson Laboratory (Stock number: 101043). The Rosa26
Motley knock-in construct was generated using components of the Brainbow-1.1"M" and Brainbow-1.0"L" plasmids ( 24 ) . The Rosa26
Motley allele was generated from V6.5 ES cells using standard methods. Long-range PCR and Southern blotting identifi ed correctly targeted clones. The MIT and Stanford Institutional Animal Care and Use Committees approved all animal studies and procedures.
Tumor Initiation and Quantifi cation
Tumors were initiated by intratracheal infection of mice with adenoviral and lentiviral vectors expressing Cre recombinase as previously described ( 32 ) . Adenoviral-Cre (Ad5-CMV-Cre) was from the University of Iowa Gene Transfer Core. Lentiviral-barcode-Cre (Lenti-BC-Cre) was generated as previously described ( 16 ) . Tumor area, lung area, as well as Nkx2-1 positive and Nkx2-1 negative areas, were determined using ImageJ. Tomato positive cancer cell number was determined using IHC staining and direct counting. The recombination effi ciency of the p53 fl ox and Kras LSL-G12D alleles and the ratio of tumor cells to normal cells at early and late lung adenocarcinoma tumor stages were determined using semiquantitative PCR.
Cell Isolation, Flow Cytometry, and Cell Sorting
Cells within the pleural cavity were collected immediately after euthanasia by making a small incision in the ventral aspect of the diaphragm followed by introduction of 1 mL of PBS. One third of the recovered pleural cavity cells were used for fl ow cytometry. Approximately 0.5 mL of blood was collected from the carotid artery. Primary tumors and metastases were dissociated as previously described ( 16 ) . Cells were stained with antibodies to CD45 (30-F11), CD31 (390), F4/80 (BM8), and Ter119 (all from BioLegend) to exclude hematopoietic and endothelial cells. DAPI was used to exclude dead cells. Cell analysis and sorting were performed on BD LSR II analyzers and FACSAria sorters (BD Biosciences).
Transplantation
To assess the tumor-seeding ability of cancer cells from the pleural cavity, one fourth of the total unsorted pleural cells were injected intravenously into the lateral tail vein of syngeneic recipient animals. Recipient mice were analyzed 3 months after transplantation. 
Barcode PCR and qRT-PCR on Sorted Cancer Cells
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sequences were PCR amplifi ed from genomic DNA and directly sequenced or TOPO cloned (Invitrogen) and sequenced. Fluidigm qRT-PCR was performed on 2 ng of total RNA from each sample. Site-specifi c target amplifi cation and real-time PCR was performed on the Fluidigm BioMark HD using Taqman primer probe sets for Nkx2-1 (Mm00447558_m1) and Sftpb (Mm00455672_g1; Applied Biosystems) using standard methods. Samples were run in quadruplicate and normalized to the average of three housekeeping genes [ Rpl27 (Mm01245874_g1), Rps29 (Mm02342448_gH), and Actb (Mm01205647_g1)].
Histologic Preparation and IHC
Samples were fi xed in 4% formalin in PBS overnight and transferred to 70% ethanol until paraffi n embedding. IHC was performed on 4-μm sections with the ABC Vectastain Kit (Vector Laboratories) with antibodies to Nkx2.1 (Epitomics; EP1584Y), Tomato (Rockland Immunochemicals; 600-401-379), cleaved caspase-3 (Cell Signaling; 9661), BrdUrd (BD Pharmingen; 555627), Ki67 (BD Pharmingen; 550609), SP-B (Santa Cruz Biotechnology; sc-13978), H3P (Serine 10; Millipore; 06-570), and cytokeratin (Sigma-Aldrich; clone PCK-26). Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining was performed using the In Situ Cell Death Detection Kit (Roche; 11684817910). Sections were developed with DAB and counterstained with hematoxylin. For in vivo BrdUrd labeling, mice were injected intraperitoneally with 50 mg/ kg of BrdUrd 24 hours before analysis. The number of BrdUrd, Ki67, H3P, CC3, and TUNEL-positive cancer cells was quantifi ed by IHC and direct counting, taking into account the morphologic feature of cancer cells and excluding areas directly adjacent to necrotic areas.
Statistical Analysis
The Mann-Whitney test was used except when the outcome of the experiment was a categorical variable, in which case the Fisher exact test was used. 
